Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × Lisaftoclax × Clear all

Phase

Status

Recruiting 9 Unknown 4 Not yet recruiting 3 Suspended 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Cyclophosphamide 1479 Cisplatin 1399 Paclitaxel 1308 Radiotherapy 1252 Carboplatin 1238 Gemcitabine 1208 Docetaxel 1107 Bevacizumab 1022 Fluorouracil 888 Doxorubicin 780 Dexamethasone 741 Rituximab 717 Capecitabine 715 Oxaliplatin 696 Etoposide 669 pembrolizumab 657 Irinotecan 629 Filgrastim 620 Cytarabine 582 Leucovorin 573 Nivolumab 547 Vincristine 505 Prednisone 471 Cetuximab 460 Bortezomib 457 Erlotinib Hydrochloride 455 Trastuzumab 447 Methotrexate 434 Lenalidomide 426 Pemetrexed 417

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04260217 2025-08-19

MAPLE-1

Ascentage Pharma Group Inc.

Phase 1 Completed

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡